Do you use trastuzumab for patients with localized HER2+ esophageal cancer after definitive chemoRT who are not surgical candidates?  

There is currently no good evidence to support use of trastuzumab as a single agent in esophageal cancer, much less with or following definitive chemoRT.  The RTOG 1010 trial will help us to understand the role of trastuzumab in trimodality therapy setting.  Based on current evidence, I ty...

I agree with @Veena Shankaran. The RTOG 1010 study is the only study that has addressed the benefit of adding trastuzumab to chemoradiation. Patients were randomized to receive trastuzumab along with chemoRT but also as adjuvant treatment following surgery. While there have been no safety signals, t...

At this time, there is no data for adding trastuzumab to definitive treatment in non-surgical therapy for esophageal cancer.  While the addition of trastuzumab to trimodality therapy has been explored in RTOG 1010, this study has not been resulted and thus we cannot extrapolate from that trial ...